[ad_1]
The World Health Organization (WHO) has expressed concern about falsified semaglutide, a drug used to treat type 2 diabetes and obesity, after fake batches of the drug were discovered in several countries.
In October 2023, counterfeit semaglutide products, specifically the brand name Ozempic, were discovered in Brazil, the United Kingdom, and the United States.
Since 2022, WHO’s Global Surveillance and Monitoring System (GSMS) has noted an increase in reports of falsified semaglutide across regions.
Official notices and suggestions
On June 20, 2024, WHO issued its first official alert in response to the verified reports. Dr. Yukiko Nakatani, WHO Assistant Director-General for Access to Medicines and Health Products, stressed that health care professionals, regulators and the public should remain vigilant.
The advisory urged stakeholders to stop using questionable drugs and promptly report any issues to the relevant authorities.
– advertise –
Patient safety measures
To prevent counterfeit medications, patients are advised to purchase medications only through licensed healthcare providers and to avoid purchasing from unfamiliar or unverified sources, especially online.
In addition, patients should check the integrity and expiration date of the packaging before use. For semaglutide for injection, proper refrigeration is essential to maintain efficacy and safety.
related articles
[ad_2]
Source link
